Stat News: Drug makers question idea to shake up how Medicare pays for certain drugs
PCMA said the changes wouldn’t be as disruptive as others argued, and highlighted several classes of drugs
PCMA said the changes wouldn’t be as disruptive as others argued, and highlighted several classes of drugs
Pharmaceutical companies gave at least $116 million to patient advocacy groups in a single year
Mark Merritt said “we always support, as an industry, patients paying lower price at the counter…it’s an outlier practice.”
Greater competition is the answer, Mr. Merritt said, and he praised recent efforts by the Food and Drug Administration
JC Scott speaks with Doug Long, Vice President of Industry Relations at IQVIA, about the impact of COVID-19 on the pharmaceutical market. IQVIA is a world leader in using data, technology, advanced analytics and expertise to help customers drive healthcare
HEALTH EQUITY HEALTH EQUITY For America’s pharmacy benefit companies, our mission is simple: increase affordable access to prescription drugs for everyone. We believe care should be patient-focused, equitable, and affordable. LEARN MORE UNLOCKING AN AFFORDABLE FUTURE UNLOCKING AN AFFORDABLE FUTURE
©2024 PCMA. All Rights Reserved.